At meeting held on 24 July 2018
The Board of Glaxosmithkline Pharmaceuticals has recommended bonus issue of one equity share for every equity share held as on a record date to be determined. The bonus issue of equity shares will be subject to approval by the shareholders, and any other applicable statutory and regulatory approvals.The Bonus shares once allotted shall rank pari-passu in all respects and carry the same rights as the existing Equity Shares and shall be entitled to participate in full in any dividend and other corporate action, recommended and declared after the new equity shares are allotted.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
